Table 1.
Demographic and baseline clinical characteristics.
| OSA | Narcolepsy | |||
|---|---|---|---|---|
| Placebo (n = 119) |
Combined Solriamfetol (All Doses) (n = 355) |
Placebo (n = 59) |
Combined Solriamfetol (All Doses) (n = 177) |
|
| Age, mean (SD), y | 54.1 (11.4) | 53.9 (10.8) | 36.0 (15.2) | 36.3 (12.5) |
| Sex, n (%) | ||||
| Male | 77 (64.7) | 220 (62.0) | 24 (40.7) | 58 (32.8) |
| Female | 42 (35.3) | 135 (38.0) | 35 (59.3) | 119 (67.2) |
| Body mass index, mean (SD), kg/m2 | 33.1 (5.2) | 33.3 (5.3) | 29.1 (6.0) | 28.0 (5.8) |
| Race, n (%) | ||||
| White | 87 (73.1) | 274 (77.2) | 47 (80.0) | 142 (80.2) |
| Black | 26 (21.8) | 63 (17.7) | 10 (16.9) | 23 (13.0) |
| Other | 6 (5.0) | 18 (5.1) | 2 (3.4) | 12 (6.8) |
| MWT sleep latency, mean (SD),a min | 12.4 (7.2) | 12.6 (7.4) | 6.1 (5.6) | 8.0 (5.7) |
| ESS score, mean (SD) | 15.6 (3.3) | 15.1 (3.3) | 17.3 (2.8) | 17.1 (3.3) |
Data are reported for the safety population. aFor baseline mean sleep latency on MWT, OSA placebo, n = 114; OSA solriamfetol, n = 348; narcolepsy placebo, n = 58; narcolepsy solriamfetol, n = 174. ESS = Epworth Sleepiness Scale, MWT = Maintenance of Wakefulness Test, OSA = obstructive sleep apnea.